Rabies Workup

  • Author: Sandra G Gompf, MD, FACP, FIDSA; Chief Editor: Burke A Cunha, MD   more...
 
Updated: Dec 12, 2011
 

Approach Considerations

If the patient presents after an acute or recent bite

When the patient presents with a bite, wound cleansing, debridement, and careful exploration for foreign body (eg, broken tooth) are essential; this should take at least 10 minutes. Generally, leave wounds to heal by secondary intention to permit drainage of wound fluids and prevent infection.[14, 18]

If the animal to which the patient was exposed has been captured, it should be delivered to a veterinarian for further evaluation or euthanasia; state health departments can then test the unfixed brain tissue.[19]

Consult immediately with public health authorities regarding need for prophylaxis.

If the patient presents with encephalitis and suspected rabies

Skin biopsy from the nape of the neck

Rabies antigen can be detected in cutaneous nerves by direct fluorescent antibody. Consult with public health authorities, as these require specialized laboratories and shipping.

Corneal touch impression

Less preferably, scraping of corneal epithelia, or corneal touch impression, for direct fluorescence antibody can be used. This requires topical ocular anesthetic and is best performed by an ophthalmologist, under public health authority guidance on specimen preparation and transport. Corneal impression is obtained by pressing the surface of sterile glass slide gently but firmly onto the cornea. Corneal scrapings should be performed by an ophthalmologist unless none is available; epithelial cells are gently collected using a sterile loop or spatula and smeared carefully on a glass slide.

Viral cultures and polymerase chain reaction (PCR) assay

Consult with public health authorities, as these require specialized laboratories and shipping. The following may be used:

  • Saliva - Results of saliva culture for rabies virus are positive in low yield within 2 weeks of illness onset
  • Cerebrospinal fluid - After the first week of illness, 80% monocytosis is observed; protein and glucose test results are normal
  • Brain tissue - Often postmortem; staining with immunohistochemical or florescent antibody staining is definitive. Negri bodies are pathognomonic (cytoplasmic inclusion bodies reflective of accumulated virions within rabies-infected neurons). They are found in the horn of Ammon of the hippocampus and cerebral cortex

Blood gas analysis

Respiratory alkalosis resulting from hyperventilation develops in the prodromal and early acute neurologic phases of rabies; this is followed by respiratory acidosis as respiratory depression progresses

Hematology studies

Results of the white blood cell (WBC) count range from normal to elevated, with 6-8% atypical monocytes

Urinalysis

Albuminuria and sterile pyuria may be observed

Imaging studies

As the neurologic phase of rabies progresses, chest radiographs may reveal infiltrates due to aspiration, nosocomial pneumonia, acute respiratory distress syndrome, or congestive heart failure.

Findings from magnetic resonance imaging (MRI) and computed tomography (CT) scanning of the brain often indicate that no abnormalities are present.

Electroencephalography

Electroencephalography (EEG) findings include encephalopathic changes. Due to generalized vasospasm of cerebral arteries during the first week of illness, EEG amplitude may drop precipitously and mimic brain death. This may be further suggested by papillary reflex abnormalities such as anisocoria or fixed pupils due to dysautonomia. These findings may reverse with return of blood flow. A more reliable means of determining brain death in the case of rabies may therefore be cerebral arterial flow scanning that demonstrates absent flow. Brain biopsy is another option.[15, 20, 21, 22, 23]

Cardiac monitoring

Supraventricular tachycardia may be observed during cardiac monitoring. Eventually, bradycardia and cardiac arrest occur.

Future tests

The nucleic acid sequence ̶ based amplification (NASBA) technique on urine samples may be used in the future.[24, 25] The NASBA technique on saliva and CSF can be used for rapid diagnosis as early as 2 days after symptom onset.

Next

Serology

Serum rapid fluorescent focus inhibition test (RFFIT) titer results are positive in 50% of rabies cases. Results of the CSF RFFIT are antibody-positive (2-25% of serum titer) after the first week of illness.

Detection of viral RNA from saliva using PCR assay and viral antigen from brain biopsy specimens yields 100% specificity. Viral antigen assessment involving nuchal skin and corneal touch impressions have sensitivities of 67% and 25%, respectively.

In true rabies cases, however, the rise in specific neutralizing antibodies is often not documented through an RFFIT, because the victims succumb to the disease prior to mounting a response. Serologic testing is more useful to ascertain serostatus in immunized animals and humans.[14]

Previous
Next

Skin Biopsy

Nuchal skin biopsy is the most reliable test of rabies infection during the first week. Results from nuchal skin punch biopsy for immunofluorescent antibody staining are 50% positive within the first week.

Obtain a full-thickness punch biopsy from the nape of the neck and include hair follicles. Place the specimen in a sterile container with saline-soaked sterile gauze, store it at -70°C, and obtain shipping instructions for a laboratory that performs the examination.

Previous
Next

Histologic Findings

General findings on pathology include cerebral congestion and inflammation typical of encephalitis. Neuronal cell death is uncommon histopathologically.

Immunohistochemical or fluorescent antibody staining of nervous tissue, usually of unfixed brain or skin biopsy specimens with sensory nerve endings, reveals deposition of virion in the cytoplasm.

Negri bodies, seen in the image below, are observed in neurons on light microscopy and represent round cytoplasmic inclusions of assembling nucleocapsid. Only 70% of brain biopsy tissue exhibits this finding in human rabies encephalitis. Electron microscopy is more sensitive than light microscopy and reveals the characteristic bullet-shaped virion.

Hematoxylin and eosin stain of Negri body in a rabHematoxylin and eosin stain of Negri body in a rabies-infected neuron. Courtesy of the US Centers for Disease Control and Prevention.
Previous
 
 
Contributor Information and Disclosures
Author

Sandra G Gompf, MD, FACP, FIDSA  Associate Professor of Infectious Diseases and International Medicine, University of South Florida College of Medicine; Chief, Infectious Diseases Section, Director, Occupational Health and Infection Control Programs, James A Haley Veterans Hospital

Sandra G Gompf, MD, FACP, FIDSA is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Coauthor(s)

Tri M Pham, MD  Consulting Physician, Division of Infectious Diseases, Watson Clinic, Lakeland

Tri M Pham, MD is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Charurut Somboonwit, MD, FACP  Assistant Professor of Medicine, Division of Infectious Disease and International Medicine, University of South Florida College of Medicine; Director of Communicable Diseases and Clinical Research, Hillsborough County Health Department

Charurut Somboonwit, MD, FACP is a member of the following medical societies: American College of Physicians, American Medical Association, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Albert L Vincent, PhD  Associate Professor, Division of Infectious Diseases and International Health, Department of Internal Medicine, University of South Florida College of Medicine; Scientific and Research Advisor to the Division of Epidemiology, Hillsborough County Health Department

Disclosure: none None None

Chief Editor

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Additional Contributors

Leslie L Barton, MD Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Richard B Brown, MD, FACP Chief, Division of Infectious Diseases, Baystate Medical Center; Professor, Department of Internal Medicine, Tufts University School of Medicine

Richard B Brown, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Wendy Carter, DO, Division of Infectious and Tropical Medicine, University of South Florida College of Medicine

Wendy Carter, DO is a member of the following medical societies: American College of Physicians, American Medical Association, American Osteopathic Association, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Lucinda Elko, MD, Division of Infectious and Tropical Medicine, University of South Florida College of Medicine

Lucinda Elko, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Donna J Fisher, MD Assistant Professor of Pediatrics, Tufts University School of Medicine; Interim Chief, Division of Pediatric Infectious Diseases, Baystate Children's Hospital

Donna J Fisher, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Anibal Jose Maldonado, MD, Fellow, Division of Infectious Diseases and International Medicine, University of South Florida

Anibal Jose Maldonado, MD is a member of the following medical societies: American College of Physicians, American Medical Association, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Russell W Steele, MD Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Additional Contributors

Leslie L Barton, MD Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Richard B Brown, MD, FACP Chief, Division of Infectious Diseases, Baystate Medical Center; Professor, Department of Internal Medicine, Tufts University School of Medicine

Richard B Brown, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Wendy Carter, DO, Division of Infectious and Tropical Medicine, University of South Florida College of Medicine

Wendy Carter, DO is a member of the following medical societies: American College of Physicians, American Medical Association, American Osteopathic Association, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Lucinda Elko, MD, Division of Infectious and Tropical Medicine, University of South Florida College of Medicine

Lucinda Elko, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Donna J Fisher, MD Assistant Professor of Pediatrics, Tufts University School of Medicine; Interim Chief, Division of Pediatric Infectious Diseases, Baystate Children's Hospital

Donna J Fisher, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Anibal Jose Maldonado, MD, Fellow, Division of Infectious Diseases and International Medicine, University of South Florida

Anibal Jose Maldonado, MD is a member of the following medical societies: American College of Physicians, American Medical Association, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Russell W Steele, MD Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Centers for Disease Control and Prevention. Investigation of rabies infections in organ donor and transplant recipients--Alabama, Arkansas, Oklahoma, and Texas, 2004. MMWR Morb Mortal Wkly Rep. Jul 9 2004;53(26):586-9. [Medline].

  2. Srinivasan A, Burton EC, Kuehnert MJ, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. Mar 17 2005;352(11):1103-11. [Medline].

  3. Blanton JD, Palmer D, Christian KA, Rupprecht CE. Rabies surveillance in the United States during 2007. J Am Vet Med Assoc. Sep 15 2008;233(6):884-97. [Medline].

  4. Messenger SL, Smith JS, Rupprecht CE. Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States. Clin Infect Dis. Sep 15 2002;35(6):738-47. [Medline].

  5. Willoughby RE Jr, Hammarin AL. Prophylaxis against rabies in children exposed to bats. Pediatr Infect Dis J. Dec 2005;24(12):1109-10. [Medline].

  6. McLean RG. Rabies in raccoons in the Southeastern United States. J Infect Dis. Jun 1971;123(6):680-1. [Medline].

  7. National Association of State Public Health Veterinarians. Compendium of animal rabies prevention and control, 2004: National Association of State Public Health Veterinarians, Inc. (NASPHV). MMWR Recomm Rep. Jun 25 2004;53:1-8. [Medline].

  8. Moore DA, Sischo WM, Hunter A, Miles T. Animal bite epidemiology and surveillance for rabies postexposure prophylaxis. J Am Vet Med Assoc. Jul 15 2000;217(2):190-4. [Medline].

  9. Doyle TJ, Bryan RT. Infectious disease morbidity in the US region bordering Mexico, 1990-1998. J Infect Dis. Nov 2000;182(5):1503-10. [Medline].

  10. Rupprecht CE, Blass L, Smith K, et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med. Aug 23 2001;345(8):582-6. [Medline].

  11. Jackson AC. Screening of organ and tissue donors for rabies. Lancet. Dec 11-17 2004;364(9451):2094-5. [Medline].

  12. WHO. WHO expert consultation on rabies. First Report. WHO technical report series. 2004;931:1-121.

  13. WHO. WHO Guide for Rabies Pre- and Post-exposure Prophylaxis in Humans. World Health Organization. Available at http://www.who.int/rabies/PEP_prophylaxis_guidelines_June10.pdf. Accessed October 18, 2010.

  14. Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. May 23 2008;57:1-28. [Medline].

  15. Willoughby RE Jr, Tieves KS, Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med. Jun 16 2005;352(24):2508-14. [Medline]. [Full Text].

  16. McDermid RC, Saxinger L, Lee B, et al. Human rabies encephalitis following bat exposure: failure of therapeutic coma. CMAJ. Feb 26 2008;178(5):557-61. [Medline]. [Full Text].

  17. Hu WT, Willoughby RE Jr, Dhonau H, Mack KJ. Long-term follow-up after treatment of rabies by induction of coma. N Engl J Med. Aug 30 2007;357(9):945-6. [Medline].

  18. Goldstein EJ. Current concepts on animal bites: bacteriology and therapy. Curr Clin Top Infect Dis. 1999;19:99-111. [Medline].

  19. Baer GM. The Natural History of Rabies. Boston, MA: CRC Press; 1991.

  20. Hantson P, Guérit JM, de Tourtchaninoff M, et al. Rabies encephalitis mimicking the electrophysiological pattern of brain death. A case report. Eur Neurol. 1993;33(3):212-7. [Medline].

  21. Hemachudha T. Human rabies: clinical aspects, pathogenesis, and potential therapy. Curr Top Microbiol Immunol. 1994;187:121-43. [Medline].

  22. Willoughby RE, Roy-Burman A, Martin KW, et al. Generalised cranial artery spasm in human rabies. Dev Biol (Basel). 2008;131:367-75. [Medline].

  23. University of Wisconsin. Care of rabies. Version 3.1. Available at http://www.mcw.edu/FileLibrary/Groups/Pediatrics/InfectiousDiseases/Milwaukee_rabies_protocol_V3_1.pdf. Accessed September 2011.

  24. Wacharapluesadee S, Hemachudha T. Nucleic-acid sequence based amplification in the rapid diagnosis of rabies. Lancet. Sep 15 2001;358(9285):892-3. [Medline].

  25. Wacharapluesadee S, Hemachudha T. Urine samples for rabies RNA detection in the diagnosis of rabies in humans. Clin Infect Dis. Mar 15 2002;34(6):874-5. [Medline].

  26. WHO. Guide for post-exposure prophylaxis. World Health Organization. Available at http://www.who.int/rabies/human/postexp/en/. Accessed October 18, 2010.

  27. World Health Organization. Rabnet Database. Department of Communicable Diseases Surveillance and Response. Animal and Food related Public Health Risks. Geneva, Switzerland: World Health Organization; 2001:[Full Text].

  28. Rupprecht CE, Gibbons RV. Clinical practice. Prophylaxis against rabies. N Engl J Med. Dec 16 2004;351(25):2626-35. [Medline].

  29. Fisher DJ. Resurgence of rabies. A historical perspective on rabies in children. Arch Pediatr Adolesc Med. Mar 1995;149(3):306-12. [Medline].

  30. Committee on Infectious Diseases, American Academy of Pediatrics. 2006 Red Book - Report of the Committee on Infectious Diseases. 27. Elk Grove, IL: American Academy of Pediatrics; 2006:552-9.

  31. Arya SC, Agarwal N. Assessing the safety of post-exposure rabies immunization in pregnancy. Hum Vaccin. Sep-Oct 2007;3(5):155; author reply 155. [Medline].

  32. Abazeed ME, Cinti S. Rabies prophylaxis for pregnant women. Emerg Infect Dis. Dec 2007;13(12):1966-7. [Medline]. [Full Text].

  33. Complete List of Vaccines Licensed for Immunization and Distribution in the U.S. Food and Drug Administration. Available at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm.

  34. Willoughby RE Jr. "Early death" and the contraindication of vaccine during treatment of rabies. Vaccine. Nov 27 2009;27(51):7173-7. [Medline].

  35. Centers for Disease Control and Prevention. Recovery of a patient from clinical rabies--Wisconsin, 2004. MMWR Morb Mortal Wkly Rep. Dec 24 2004;53(50):1171-3. [Medline]. [Full Text].

  36. Dandoy S, Scanlon F. Teaching kids about rabies. Am J Public Health. Mar 1999;89(3):413-4. [Medline].

  37. Murray KO, Arguin PM. Decision-based evaluation of recommendations for preexposure rabies vaccination. J Am Vet Med Assoc. Jan 15 2000;216(2):188-91. [Medline].

  38. Moran GJ, Talan DA, Mower W, et al. Appropriateness of rabies postexposure prophylaxis treatment for animal exposures. Emergency ID Net Study Group. JAMA. Aug 23-30 2000;284(8):1001-7. [Medline].

  39. Prosniak M, Faber M, Hanlon CA, et al. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis. Jul 1 2003;188(1):53-6. [Medline].

  40. Wilson JM, Hettiarachchi J, Wijesuriya LM. Presenting features and diagnosis of rabies. Lancet. Dec 6 1975;2(7945):1139-40. [Medline].

  41. A Human Monoclonal Antibody to Rabies Virus Provides Protective Neutralizing Activity: Results of a Phase 1 Study, 50th Annual Meeting, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, MA, 2010.

  42. World Health Organization. Rabies. 2006;Fact Sheet #99:[Full Text].

Previous
Next
 
Hematoxylin and eosin stain of Negri body in a rabies-infected neuron. Courtesy of the US Centers for Disease Control and Prevention.
Distribution of the 5 strains of rabies virus and the associated wildlife in the United States.
Table 1. Risk Categories for Active Preexposure Immunization and Rabies Titer Monitoring
CategoryTarget PopulationImmunization RegimenSerologic Testing
ContinuousRabies research laboratory or biologics production workersPrimary course; booster when serum antibody is less than 1:5 dilution based on RFFIT resultsEvery 6 months
FrequentRabies diagnostic laboratory workers, spelunkers, veterinarians and staff, animal control and wildlife workers in rabies-enzootic areas, travelers to areas of enzootic rabies for more than 30 days Primary course; booster every 2 years or when serum antibody is less than 1:5 dilution based on RFFIT resultsEvery 2 years if not regularly boosted
InfrequentVeterinarians and staff/students, animal control and wildlife workers in areas of low rabies riskPrimary course; no boosterNone
RareUS population at largeNoneNone
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.